Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Selenious Acid
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Selenious Acid Injection is a trace element indicated in adult and pediatric patients as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2022
Lead Product(s) : Selenious Acid
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zinc,Copper,Selenious Acid
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Launches Multrys™ (trace elements injection 4*, USP)
Details : Multrys™ is indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Product Name : Multrys
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 02, 2021
Lead Product(s) : Zinc,Copper,Selenious Acid
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selenious Acid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Pharco Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Selenious acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 03, 2021
Lead Product(s) : Selenious Acid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Pharco Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable